Drug Trial Radar · NCT06182696
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
Last checked: Nov 19, 2026Latest source record: May 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
83
Planned (sponsor's estimate)
Start
Oct 26, 2023
Primary completion
Nov 30, 2026
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- OriCell Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open label, dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of OriCAR-017 in R/RMM
Conditions
- Relapsed and/or Refractory Multiple Myeloma
Interventions
OriCAR-017Biological
GPCRC5D-directed chimeric antigen receptor modified T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose of OriCAR-017-P1Time frame: Up to 28 days
- Dose-limiting toxicity (DLT)Time frame: Up to 28 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Beijing GoBroad Hospital
Beijing, China · Not yet recruiting
The First Affiliated Hospital with Nanjing Medical University
Nanjing, China · Not yet recruiting
Tongji Hospital of Tongji University
Shanghai, China · Not yet recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China · Recruiting
The First Affiliated Hospital College of Medicine Zhejiang University
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.